Furthermore, clinical trials using humanized anti-CD6 mAbs have provided valuable information regarding the potential targeting of CD6 for the treatment of RA but also psoriasis and potentially other T cell–driven autoimmune diseases (55–57). Here, CD6 is linked to rheumatoid arthritis.